Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT05163626

Combined Aerobic Exercise and Cognitive Training in Seniors at Increased Risk for Alzheimer's Disease

The study aims to investigate the effect of a long-term combined aerobic exercise and cognitive training program on cognitive function and blood exosomal synaptic protein levels in seniors at increased risk for Alzheimer's Disease.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

Alzheimer's disease (AD) is the most common cause of dementia in people older than 65 years worldwide. The neuropathological changes of AD occur decades before the onset of cognitive impairment, suggesting that early identification and timely intervention may postpone the clinical progress. In addition to its characteristic amyloid β and tau pathology, AD is also marked by synaptic dysfunction. Abnormal synaptic protein levels, such as growth associated protein 43 (GAP43), neurogranin, synaptotagmins, and synaptosome associated protein 25 (SNAP25) have been observed in the brain tissue and cerebrospinal fluid (CSF). Blood neuro-exosomal synaptic proteins have emerged as promising predictors for AD and cognitive decline. Particularly, the investigators previously reported a combination of blood neuro-exosomal protein (GAP43, neurogranin, SNAP25, and synaptotagmin 1) can predict AD 5 to 7 years before the clinical onset.

Both physical exercise and cognitive training have been demonstrated to improve cognitive function in AD and to exert a protective effect against developing dementia in the normal aging population. Furthermore, cognitive stimulation is an established modulator of synaptic plasticity and physical exercise might regulate synapse functional and structural change. However, whether cognitive training and physical exercise can alter exosomal synaptic protein levels and the relationship of biomarker changes to cognitive function in those seniors at increased risk for AD remain unclear.

In this study, the investigators aim to

  • assess the effects of a long-term combined aerobic exercise and cognitive training program on cognitive function and the predictive biomarkers (blood neuro-exosomal synaptic proteins: GAP43, neurogranin, SNAP25, and synaptotagmin 1) in seniors at increased risk of AD with abnormally decreased levels of the biomarkers.
  • determine the relationship of biomarker changes with cognitive function in these people.
  • confirm the predictive value of the blood neuro-exosomal synaptic proteins for AD in a longitudinal setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Mandarin-speaking subjects.
  • Not clinically demented.
  • Meeting the cutoff values of MMSE and CDR.
  • With low levels of blood neuro-exosomal synaptic proteins (GAP43<1983pg/ml, synaptotagmin 1<431pg/ml, neurogranin<1433pg/ml, SNAP25<448pg/ml)

Exclusion criteria

  • Had major neurologic diagnosis (e.g., Alzheimer's disease, Parkinson's disease, stroke, encephalitis, and epilepsy) or other condition that might impair cognition or confound assessments.
  • Had a history of psychotic episodes or had major depression (Hamilton Depression Rating Scale score > 24 points).
  • Had severe systemic diseases, such as tumors, cardiovascular or orthopedic disorders that can affect the ability to perform the proposed intervention tasks.

Treatment and study plan

Combined aerobic exercise and cognitive training program

Behavioral

Participants will take part in a combined aerobic exercise and cognitive training program. The program will include moderate cycling exercise and cognitive game resolving at the same time. The tasks will be instructed and supervised by a fitness expert and a trained clinical neuropsychologist.

Primary outcomes

  1. Change in cognitive function over time as assessed by the Montreal Cognitive Assessment (MoCA)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    MoCA will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  2. Change in cognitive function over time as assessed by Mini Mental State Examination (MMSE)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    MMSE will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  3. Change in cognitive function over time as assessed by Clinical Dementia Rating (CDR)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    CDR will be performed to evaluate the cognition of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 18, with higher values indicating worse cognition.

  4. Change in cognitive function over time as assessed by Verbal Fluency Test

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Verbal Fluency Test will be performed to evaluate the semantic memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce as many animals as possible within 1 minute. The score is the number of animals, with higher scores indicating better cognition.

  5. Change in cognitive function over time as assessed by Digit Span Test-Forward and Backward

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Digit Span Tests will be performed to evaluate the working memory of participants at the enrollment and year 1, year 3, year 5, year 7. The total scores are twelve for each test, with higher values indicating better cognition.

  6. Change in cognitive function over time as assessed by Trail-Making Test Parts A and B (TMT-A and TMT-B)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    TMT-A and TMT-B will be performed to evaluate the executive function of participants at the enrollment and year 1, year 3, year 5, year 7. Scoring is based on time taken to complete the test (e.g., 35 seconds yielding a score of 35), with lower scores indicating better cognition.

  7. Change in cognitive function over time as assessed by Boston Naming Test (BNT)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    BNT will be performed to evaluate the language function of participants at the enrollment and year 1, year 3, year 5, year 7. The score ranges from 0 to 30, with higher values indicating better cognition.

  8. Change in cognitive function over time as assessed by the Rey-Osterrieth Complex Figure Test (ROCF)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    ROCF will be performed to evaluate the visuospatial function and other cognition domains of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to produce a complicated line drawing, with higher scores indicating better cognition.

  9. Change in cognitive function over time as assessed by California Verbal Learning Test (CVLT)

    Time frame: baseline time, year 1, year 3, year 5, year 7

    CVLT will be performed to evaluate the memory function of participants at the enrollment and year 1, year 3, year 5, year 7. Participants are asked to finish immediate recall, delayed recall, and delayed recognition tasks in the test, with higher scores indicating better cognition.

Secondary outcomes

  1. Changes in concentrations of blood neuro-exosomal GAP43 over time

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Concentrations of blood neuro-exosomal GAP43 will be evaluated at the enrollment and year 1, year 3, year 5, year 7, and measured in pg/ml.

  2. Changes in concentrations of blood neuro-exosomal neurogranin over time

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Concentrations of blood neuro-exosomal neurogranin will be evaluated at the enrollment and year 1, year 3, year 5, year 7, and measured in pg/ml.

  3. Changes in concentrations of blood neuro-exosomal SNAP25 over time

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Concentrations of blood neuro-exosomal SNAP25 1 will be evaluated at the enrollment and year 1, year 3, year 5, year 7, and measured in pg/ml.

  4. Changes in concentrations of blood neuro-exosomal synaptotagmin1 over time

    Time frame: baseline time, year 1, year 3, year 5, year 7

    Concentrations of blood neuro-exosomal synaptotagmin1 will be evaluated at the enrollment and year 1, year 3, year 5, year 7, and measured in pg/ml.

  5. The area under curve of the blood neuro-exosomal synaptic proteins (GAP43, neurogranin, SNAP25, and synaptotagmin1) for the accurate diagnosis of AD

    Time frame: up to 7 years

    The area under curve is used to show the ability of the blood neuro-exosomal synaptic proteins (GAP43, neurogranin, SNAP25, and synaptotagmin1) to diagnose AD. The value of area under curve is higher, then the ability of the blood neuro-exosomal synaptic proteins to diagnose AD is stronger.

Study contacts

Contact information is provided by the study sponsor or research team.

Longfei Jia, MD,PhD

CONTACT

[email protected]

+86 10 83199456

Sponsors and collaborators

Lead sponsor

Xuanwu Hospital, Beijing

Other

Registry information

Official study title

Combined Aerobic Exercise and Cognitive Training for Alzheimer's Disease Prevention in At-Risk Seniors Estimated by An Exosomal Synaptic Protein Model: Cognition and Exosomal Synaptic Proteins Effects

Important dates

Study start
2024
Primary completion
2034
Study completion
2034
First posted
Dec 20, 2021
Registry last updated
Jul 24, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.